Clinical trial · Interventional
Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid Metaplasia
Allogeneic Bone Marrow Transplantation for Patients With Chronic Myelogenous Leukemia in the Chronic Phase or Multiple Myeloma
NCT00004181CI-TRIAL-00007159completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Bone marrow transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells. PURPOSE: Phase II trial to study the effectiveness of allogeneic bone marrow transplantation in treating patients who have multiple myeloma, chronic phase chronic myelogenous leukemia, or agnogenic myeloid metaplasia.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chronic Myeloproliferative Disorders | Myeloproliferative Neoplasm | ALIAS | 0.90 |
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Multiple Myeloma and Plasma Cell Neoplasm | — | UNRESOLVED | — |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| allogeneic bone marrow transplantation | Procedure | — | UNRESOLVED |
| busulfan | Drug | Busulfan | ALIAS |
| cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| radiation therapy | Radiation | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 55 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Cytologically proven disease of one of the following types with transfusion-dependent anemia or thrombocytopenia (less than 50,000/mm\^3):
* Multiple myeloma
* Agnogenic myeloid metaplasia
* Chronic myelogenous leukemia in first or second chronic phase
* Philadelphia chromosome with BCR gene rearrangement
* Suitable sibling bone marrow donor available
PATIENT CHARACTERISTICS:
Age:
* 15 to physiologic 55
Performance status:
* ECOG 0 or 1
Life expectancy:
* Not specified
Hematopoietic:
* See Disease Characteristics
Hepatic:
* Bilirubin no greater than 2.0 mg/dL
* SGOT less than 2 times normal
* Alkaline phosphatase less than 2 times normal
Renal:
* Creatinine less than 2 mg/dL
Cardiovascular:
* Ejection fraction normal by MUGA
* No acute myocardial infarction within the past 6 months
* No active angina pectoris
* No active congestive heart failure
Pulmonary:
* FEV greater than 50% predicted
* DLCO at least 50%
Other:
* HIV negative
* No active infection
* No concurrent organ damage or medical problems that would preclude therapy
PRIOR CONCURRENT THERAPY:
* Not specifiedReferences
Publications (0)
Data not yet available
No reference posted for this study.